The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
Information source: Janssen Korea, Ltd., Korea
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alzheimer Disease
Intervention: galantamine hydrobromide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Janssen Korea, Ltd., Korea Official(s) and/or principal investigator(s): Janssen Korea, Ltd. Clinical Trial, Study Director, Affiliation: Janssen Korea, Ltd.
Summary
The purpose of this study is to assess the efficacy of galantamine on the attention of
patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease
patients affects their activities of daily living, and the global benefit of galantamine.
Clinical Details
Official title: A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Attention and Executive function: Visual CPT, Visual Span, Color Trail Making test, Stroop test
Secondary outcome: Cognition: Mini-Mental Sate Examination-Korean version (MMSE-K);Activities of Daily living: Seoul- Instrumental Activities of daily livings (S-IADL);Behavior: NPI-Q;Global Change: Global Deterioration Scale (GDS)
Detailed description:
Recent studies suggest that an attention deficit occurs at early stage of Alzheimer's
disease and affects patients' activities of daily living. In other words, some patients
without language or visuospatial dysfunction have severe impairment of activities of daily
living, which might result from attention deficit. Another recent clinical study showed that
galantamine is more effective in attention and vigilance of Alzheimer's disease patients
than donepezil. The study hypothesis is that galantamine will improve attention and frontal
executive function in Alzheimer's disease patients and is well-tolerated. 8 mg/day for the
first 4 weeks, 16 mg for the next 8 weeks
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male or female patients aged 50 years or older
- Alzheimer's disease according to the criteria of DSM-IV15, NINCDS-ADRDA16
- Measuring standard MMSE-K 10 to 26
- Patients who are literate
- Dementia patients being nursed by the family
- Patients who submitted written consent before entering into the clinical trial (the
guardian consent is also effective)
Exclusion Criteria:
- If the patient was taking AChEI (Tacrine, Donepezil, Rivastigmine) to treat dementia,
the patient can enter into this clinical trial as long as he/she has not taken the
drug within 15 days of the beginning of the clinical trial
- Neurodegenerative diseases (e. g. Parkinson's disease, Pick's disease, Huntington's
disease, Down syndrome)
- Dementia related to head trauma and dementia related to brain damage due to cerebral
hypoxia (hypoxic brain damage after cardiopulmonary resuscitation, hypoxic brain
damage after surgery, hypoxic brain damage due to addiction, hypoxic brain damage due
to shock)
- brain tumor, nerve syphilis, meningitis, encephalitis, brain tumor
- amentia
- epilepsy
- major psychiatric patients such as major depression and schizophrenia
- treatment-resistant gastric and peptic ulcer
- patients with clinically serious hepatic, renal, lung, endocrinal or metabolic
disease(thyroid, parathyroid, pituitary, renal failure, diabetes mellitus)
- patients complaining of severe difficulty in urination
- patients who have undergone heart surgery within 6 months or patients who experienced
myocardial infarction, patients with untreated congestive heart failure, patients
with severe disorders in the mitral valve or aortic valve
- patients who have once taken the investigational drugs within the past 1 month from
the beginning day of the clinical trial
- patients with uncontrolled diabetes mellitus (if the patient is taking medication and
consults the doctor on a regular basis, he/she can participate in this clinical
trial)
- patients who experienced hypersensitivity or allergy by a cholinesterase inhibitor
- patients who have not given their consent to the clinical trial, patients who are
judged inappropriate to participate in this clinical trial by the investigator
Locations and Contacts
Additional Information
Starting date: March 2004
Last updated: January 20, 2011
|